NCT03860376 - Ex Vivo Drug Sensitivity Testing and Mutation Profiling | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 21, 2019

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions

Recurrent Childhood Acute Myeloid LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Large Cell LymphomaRefractory Childhood Acute Lymphoblastic LeukemiaRefractory Childhood Hodgkin LymphomaRefractory Childhood Malignant Germ Cell NeoplasmRecurrent Childhood Brain TumorRecurrent Childhood Brainstem GliomaRecurrent Childhood RhabdomyosarcomaRecurrent Childhood Soft Tissue SarcomaRecurrent Childhood EpendymomaRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood GliosarcomaRefractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Trial Locations (1)

33155

Nicklaus Children's Hospital, Miami

All Listed Sponsors

collaborator

Nicklaus Children's Hospital f/k/a Miami Children's Hospital

OTHER

lead

Florida International University

OTHER